GlassScriptPrepare for your visit
Richard A Deamicis
Internal Medicine · Chelmsford, MA · NPI 1801865233
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$4,380.96
in general payments reported to CMS, 2019-2025 · $684 in 2025
The $684 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Who reported paying
General payments only, top 6 by amount.
- Glaxosmithkline, LLC. $787.07
- Pfizer INC. $505.14
- Abbvie INC. $494.23
- Astellas Pharma US INC $322.61
- Astrazeneca Pharmaceuticals LP $277.89
- Amgen INC. $217.30
Drugs and devices associated with these payments
Nurtec Odt Xarelto Ubrelvy Zavzpret Freestyle Libre 3 Repatha Qulipta Rybelsus Farxiga Otezla Fanapt Gemtesa
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Richard Deamicis listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/263042/richard-a-deamicis